Show simple item record

dc.creatorBeljkaš, Milan
dc.creatorRebić, Jelena
dc.creatorRadan, Milica
dc.creatorĐikić, Teodora
dc.creatorOljačić, Slavica
dc.creatorNikolić, Katarina
dc.date.accessioned2023-09-28T08:14:11Z
dc.date.available2023-09-28T08:14:11Z
dc.date.issued2023
dc.identifier.isbn978-86-82172-02-4
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/5041
dc.description.abstractOverexpression of Rho-associated protein kinases has been associated with various diseases, including tumors. None of the approved ROCK inhibitors are used for cancer treatment. However, some of them have been shown to have anti-tumor potential. The main objective of this study was to develop novel ROCK1 inhibitors using the structure-based method, molecular docking, and prediction of pharmacokinetic properties using the ADMET predictor. The key interactions that strongly correlate with the activity of ROCK1 inhibitors are hydrogen bonds between amino acid residues Met156, Glu154 and the hinge region of the inhibitors, indicating possible structural changes in the hinge region of studied compounds. On the other hand, the lack of interactions between 1,3-benzoxadiol moiety and the enzyme presents a promising approach for further structural modifications in order to design more effective ROCK1 inhibitors. All the important interactions between the developed ROCK1 inhibitors and the binding site of the enzyme were established. They also showed acceptable pharmacokinetic properties and could be further used for synthesis and evaluation by various biological assays.sr
dc.language.isoensr
dc.publisherInstitute for Information Technologies, University of Kragujevac, Serbiasr
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200161/RS//sr
dc.rightsopenAccesssr
dc.source2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGSsr
dc.subjectmolecular dockingsr
dc.subjectADMEsr
dc.subjectdesignsr
dc.subjectROCK1sr
dc.titleVirtual Docking, design and in silico ADMET profiling of novel Rho- associated protein kinases-1 (ROCK1) inhibitorssr
dc.typeconferenceObjectsr
dc.rights.licenseARRsr
dc.citation.spage1589
dc.citation.epage1592
dc.description.other2nd International Conference on Chemo and Bioinformatics, September 28-29, 2023. Kragujevac, Serbiasr
dc.identifier.doi10.46793/ICCBI23.589B
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs/bitstream/id/13892/Virtual_Docking,_design_pub_2023.pdf
dc.type.versionpublishedVersionsr


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record